Leading Dermatologists Develop Consensus Guidelines for the Use of Superficial Radiation Therapy to Treat Non-Melanoma Skin Cancers and Keloids
Published in The Journal of Clinical and Aesthetic Dermatology, Consensus was Reached that SRT is Safe, and Effective in Treating SCC and BCC and Should be Considered as the First-Line Form of Radiation Treatment. BOCA RATON, Fla., Feb. 14, 2019 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment […]
Leading Dermatologists Develop Consensus Guidelines for the Use of Superficial Radiation Therapy to Treat Non-Melanoma Skin Cancers and Keloids
Published in The Journal of Clinical and Aesthetic Dermatology, Consensus was Reached that SRT is Safe, and Effective in Treating SCC and BCC and Should be Considered as the First-Line Form of Radiation Treatment. BOCA RATON, Fla., Feb. 14, 2019 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment […]
Modern Medicine – Dr. Brian Berman discusses the problem with keloids.
Researchers found in a retrospective study of 297 surgically excised keloids with superficial radiation therapy around the excision site that only 3% recurred during an average 6-month follow-up. Read the full article here.
Cure Rate Exceeds 97 Percent in Retrospective Study of Sensus Healthcare’s SRT-100™ for Treating Basal and Squamous Cell Carcinomas of the Lower Extremities
Data from this Non-Invasive, Highly Effective Treatment Option for Non-Melanoma Skin Cancer Published in Journal of Drugs in Dermatology BOCA RATON, Fla., Feb. 12, 2019 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radio Therapy (IGSRT), announces the […]
Cure Rate Exceeds 97 Percent in Retrospective Study of Sensus Healthcare’s SRT-100™ for Treating Basal and Squamous Cell Carcinomas of the Lower Extremities
Data from this Non-Invasive, Highly Effective Treatment Option for Non-Melanoma Skin Cancer Published in Journal of Drugs in Dermatology BOCA RATON, Fla., Feb. 12, 2019 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radiation Therapy (IGSRT), announces the […]
Cure Rate Exceeds 97 Percent in Retrospective Study of Sensus Healthcare’s SRT-100™ for Treating Basal and Squamous Cell Carcinomas of the Lower Extremities
Data from this Non-Invasive, Highly Effective Treatment Option for Non-Melanoma Skin Cancer Published in Journal of Drugs in Dermatology BOCA RATON, Fla., Feb. 12, 2019 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radiation Therapy (IGSRT), announces the […]